Does LENOGRASTIM Cause Second primary malignancy? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Second primary malignancy have been filed in association with LENOGRASTIM (GUNA-GCSF). This represents 0.8% of all adverse event reports for LENOGRASTIM.
6
Reports of Second primary malignancy with LENOGRASTIM
0.8%
of all LENOGRASTIM reports
4
Deaths
0
Hospitalizations
How Dangerous Is Second primary malignancy From LENOGRASTIM?
Of the 6 reports, 4 (66.7%) resulted in death, and 1 (16.7%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LENOGRASTIM. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does LENOGRASTIM Cause?
Pyrexia (95)
Vomiting (61)
Neutropenia (59)
Dyspnoea (55)
Fatigue (55)
Nausea (53)
Pneumonia (51)
Arthralgia (50)
Febrile neutropenia (50)
Off label use (50)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LENOGRASTIM Alternatives Have Lower Second primary malignancy Risk?
LENOGRASTIM vs LENVATINIB
LENOGRASTIM vs LEPONEX
LENOGRASTIM vs LERCANIDIPINE
LENOGRASTIM vs LETAIRIS
LENOGRASTIM vs LETERMOVIR